Readout AI, a pioneering company in the field of clinical trial analysis using artificial intelligence (AI), has successfully completed its pre-seed funding round. Meridian Street Capital led the round, with participation from Mucker Capital, Necessary Ventures, and angel investor Ryan Fukushima, who serves as the COO of Tempus and CEO of Pathos. The funding will enable Readout AI to accelerate product development, enhance AI capabilities, and expand its talented team.
The primary focus of Readout AI's pre-seed financing is to advance the development of AI solutions tailored for clinical trial analysis. Drawing on the expertise of professionals in AI and pharmaceutical services, the company firmly believes that AI has the potential to revolutionise the biostatistical and medical writing tasks associated with clinical trials.
"We are thrilled to have secured funding from such influential and supportive investors," expressed Matthew Michelson, PhD, CEO of Readout AI. "This investment validates our vision and underscores the immense impact our technology can have in improving the efficiency of clinical trials."
Readout AI's platform leverages automated data analysis techniques, employing appropriate statistical methods, and transforming the results into various formats such as table descriptions, abstracts, and posters. The ultimate goal is to alleviate the bottlenecks encountered during clinical data analysis and reporting by swiftly converting trial data into easily understandable insights for human readers.
Michael Shleifer, PhD, co-founder of Readout AI, emphasised a unique aspect of their application: "An often overlooked area where technology can make a significant difference is trial progression and performance analysis. While most attention is typically directed towards patient recruitment and final results, Readout's AI can also contribute to analysing and reporting on the progression of trials, which represents a novel advancement."
Scott Law, General Partner at Meridian Street Capital, expressed confidence in Readout AI's potential: "Readout AI aligns perfectly with our belief that AI can fundamentally transform the healthcare landscape. By utilising AI to enhance the productivity of biostatistics and medical writing, we can accelerate the delivery of critical insights derived from trial data."
With this successful funding round, Readout AI is well-positioned to continue pushing the boundaries of AI in clinical trial analysis, delivering impactful advancements that have the potential to shape the future of healthcare.
Click here to read the original news story.